3-(4-((1E)-3-(2-aminophenylamino)-3-oxoprop-1-en-1-yl)phenyl)-2-(4-fluorophenyl)-N,N-dimethylacrylamide | 1147867-81-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-(4-((1E)-3-(2-aminophenylamino)-3-oxoprop-1-en-1-yl)phenyl)-2-(4-fluorophenyl)-N,N-dimethylacrylamide
• 英文别名: (E)-3-[4-[(E)-3-(2-aminoanilino)-3-oxoprop-1-enyl]phenyl]-2-(4-fluorophenyl)-N,N-dimethylprop-2-enamide
• CAS: 1147867-81-9
• 化学式: C₂₆H₂₄FN₃O₂
• 分子量: 429.494
• InChiKey: JYXFMBKLBZMROR-JWJKVXABSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• HISTONE DEACETYLASE INHIBITORS
  申请人：Rajagopal Sridharan

  公开号：US20100291003A1

  公开（公告）日：2010-11-18

  Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).

  具有组合式（I）的新化合物，具有组蛋白去乙酰化酶（HDAC）抑制酶活性，其衍生物，类似物，互变异构体，立体异构体，多晶形，水合物，溶剂化物，中间体，药学上可接受的盐，制药组合物，代谢物和其前药。本发明特别提供了一种具有组合式（I）的新化合物。还包括一种治疗癌症，银屑病，增生性疾病和由HDAC介导的疾病的方法，其中包括向哺乳动物中投与组合式（I）的新化合物的有效量。
• US8450525B2
  申请人：——

  公开号：US8450525B2

  公开（公告）日：2013-05-28
• [EN] HISTONE DEACETYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：ORCHID RES LAB LTD

  公开号：WO2009053808A2

  公开（公告）日：2009-04-30

  Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).